62.
Osteosarcoma: 30 Years’ Experience from a Single Institution’s
Population-based Database
Ninna Aggerholm-Pedersen, Katja Maretty-Nielsen, Johnny Keller, Henrik
Schrøder, Steen Bærentzen, Akmal Safwat
Department of Experimental Clinical Oncology Sarcoma Centre of Aarhus
University Hospital; Department of Experimental Clinical Oncology, Sarcoma
Centre of Aarhus University Hospital; Department of Orthopaedics, Sarcoma
Centre of Aarhus University Hospital; Department of Paediatrics, Sarcoma
Centre of Aarhus University Hospital; Department of Pathology, Sarcoma
Centre of Aarhus University Hospital; Department of Oncology, Sarcoma
Centre of Aarhus University Hospital
Background:
Treatment of osteosarcoma remains a major challenge in
orthopedic oncology.
Purpose / Aim of Study:
The aim of the study was to assess the incidence,
survival rates and prognostic factors of osteosarcoma from a single institution
in a population-based database.
Materials and Methods:
For the present study, data of patients diagnosed
with osteosarcoma in Denmark from 1979-2009 were extracted from the
Aarhus Sarcoma Registry (ASR) and compared to the population-based Danish
Cancer Registry.
Findings / Results:
188
patients with osteosarcoma were registered,
corresponding to 97% of all patients diagnosed with osteosarcoma in Jutland.
In the following analysis, only patients with high-grade osteosarcoma were
included. From 1979 to 1988, most patients were treated with primary
amputation. The 5-years overall survival (OS) for patients with localized
disease in this period was 41.1%, compared to 58.5% for patients treated in the
second time period, 1989-1998. The OS for patients aged 40 or older was
significantly poorer than for patients under the age of 40, with median survival
of 11 months and 45 months respectively. The median OS for patients with
localized disease was 40 months compared to 15 months for patients with only
lung metastases at the time of diagnosis, and further reduced to 6.6 months for
patients who presented with metastasis to other sites +/- lung metastasis. The
OS for patients with late relapse (2 years and more after primary diagnosis)
was significantly better compared to patients with early relapse, with a 5-year
OS of 59.2% and 11.4%, respectively.
Conclusions:
The crude incidence was 0.23/100.000/year. The 5-year OS of
patients with high-grade osteosarcoma was dependent on the year of diagnosis,
age, stage at the time of diagnosis and soft tissue extension. Time to relapse
was a strong prognostic factor for OS after recurrence.
